Akili Interactive, a prescription digital medicine company, and the University of California, San Francisco (UCSF) announced the issuance of patents broadly covering Akili’s proprietary platform technology that “adaptively delivers a range of stimuli designed to target specific networks in the brain.”
“The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,940,844 and the Japan Patent Office (JPO) has issued Patent Nos. 6177131 and 6297096,” said Akili.
“The patents will provide protection in the United States and Japan until 2032 and 2031, respectively.”
Akili CEO Eddie Martucci said: “These new patents, along with several other patent applications currently under review worldwide, recognize the strength of Akili’s innovation and our novel approach to assessing and treating cognitive dysfunction present across a number of medical conditions.
“Equally important, these patents demonstrate that the active technology components of a new digital medicine can be protected just as you would a novel pharmaceutical, which we believe is essential for the advancement of the field toward becoming mainstream medicine.”
Akili said the patents were issued to the Regents of the University of California and the inventor is Adam Gazzaley, Founding Director of Neuroscape at UCSF and Akili’s Chief Science Advisor.
“Akili has exclusive worldwide rights to the technology,” said Akili.
“This licensing deal was negotiated in 2013 with the Office of Technology Management, now within UCSF Innovation Ventures, which leads licensing and business development efforts on behalf of the university.
“The patents are part of an expanding and comprehensive portfolio of patent applications and other intellectual property covering Akili’s platform technology which clinical studies show can result in the targeted activation of specific neural systems in the brain to treat diseases with associated cognitive dysfunction.
“The U.S. and Japan patents broadly cover the unique mechanism of presenting a range of specific stimuli that engage targeted neural networks in the prefrontal cortex, the area of the brain known to play a key role in cognitive control, to assess and improve cognitive abilities.
“The digital mechanism also implements algorithms that adapt in both real-time and between treatment sessions in a closed-loop system to automatically adjust the level – or dose – for a personalized treatment experience that is adapted to the needs of each individual patient.”